Esco Aster provides comprehensive investor and technical due diligence services across the biotechnology, pharmaceutical, advanced therapeutics, medical technology, nutrition, dermocosmetic, and healthcare sectors. We act as an independent technical advisor to stakeholders across the innovation ecosystem, including venture capital funds, family offices, corporate venture capital, government agencies, grant bodies, technology transfer offices (TTOs), incubators, accelerators, research institutions, universities, hospitals, nonprofit organizations, and startup founders.
Our multidisciplinary expertise spans scientific, technical, manufacturing, regulatory, commercial, and operational domains, enabling us to provide objective, evidence-based assessments that support informed investment, funding, licensing, and commercialization decisions.
Beyond evaluating investment opportunities, we prepare companies for investor scrutiny by strengthening their scientific narrative, commercial strategy, data room, and overall investment readiness. We also work closely with researchers, universities, and technology transfer offices to identify commercially viable intellectual property, support spinout formation, and build investor-ready ventures capable of attracting institutional capital.
Where required, Esco Aster supplements advisory engagements with fractional executive leadership, providing experienced interim executives who help companies execute against the recommendations identified during due diligence.
Life science investments require significantly more than financial analysis. Success depends upon the ability to assess scientific validity, intellectual property strength, manufacturing scalability, regulatory strategy, commercial feasibility, reimbursement potential, competitive positioning, and execution capability simultaneously.
Emerging sectors such as cell therapy, gene therapy, exosome therapeutics, microbiome therapeutics, clinical nutrition, cultivated meat, nutraceuticals/supplements, nutricosmetics and dermocosmetics are characterised by rapid scientific advances, evolving regulatory frameworks, complex manufacturing processes, and high development costs. Investors and grant agencies often lack the specialist expertise required to evaluate these risks comprehensively.
Esco Aster provides an independent, multidisciplinary due diligence framework that evaluates both opportunity and execution risk across the entire product and company lifecycle.
Our assessments help stakeholders:
By identifying risks early and providing practical mitigation strategies, we help improve capital allocation, increase the probability of technical success, and maximise long-term enterprise value.
Our due diligence framework integrates scientific, technical, regulatory, operational, and commercial assessments into a single comprehensive evaluation.
We evaluate the scientific rationale supporting the technology, including mechanism of action, supporting publications, reproducibility of experimental data, product differentiation, and technology maturity. We assess whether available evidence supports the proposed therapeutic claims and whether the underlying science is sufficiently robust for further development.
We assess patent portfolios, licensing structures, freedom-to-operate considerations, intellectual property strategy, and technology positioning. We identify opportunities to strengthen patent protection while evaluating the commercial attractiveness of the underlying assets.
Leveraging Esco Aster's expertise in advanced biomanufacturing, we evaluate:
Our assessments determine whether manufacturing can support successful clinical development, commercialisation, reimbursement, and long-term profitability.
We review regulatory strategy against global agency expectations, including FDA, EMA, PMDA, MHRA, HSA, TGA, KFDA, Pic/s, NMPA, and other Asean regulatory authorities. Assessments include:
We evaluate the resilience and sustainability of the manufacturing supply chain, including critical raw materials, plasmids, viral vectors, starting cell lines, media, consumables, and contract manufacturing capabilities. We identify vulnerabilities and recommend mitigation strategies to improve supply security and operational resilience.
Successful biotechnology companies depend on exceptional leadership.
We assess:
Where necessary, we recommend organisational improvements and can provide interim executive leadership to bridge capability gaps.
We evaluate:
We benchmark the company against competing therapeutic modalities to determine whether the technology can achieve sustainable competitive advantage and long-term commercial success.
Our due diligence engagements typically include:
We help researchers translate scientific discoveries into commercially viable technologies by incorporating Target Product Profiles (TPP), Quality Target Product Profiles (QTPP), CMC strategy, manufacturability, and commercial considerations early in development. This increases the value of intellectual property while improving the likelihood of successful translation.
We prepare founders for institutional fundraising by strengthening scientific positioning, commercial strategy, regulatory planning, and investor communications. Through executive coaching and fractional leadership, we help founders think like investors, improve due diligence readiness, and build companies designed for long-term value creation and successful exit.
We support polytechnics, universities, institutes of higher learning, national cancer centres, national skin centres, specialty medical centres, university hospitals, healthcare systems, and research institutions in evaluating invention disclosures, prioritising patent investments, assessing commercial potential, developing spinout strategies, and building globally competitive ventures.
Our assessments include intellectual property strategy, freedom-to-operate, licensing considerations, and venture formation planning.
We provide independent technical due diligence for venture capital funds, family offices, corporate investors, and strategic partners that may not possess extensive in-house biotechnology expertise.
Our multidisciplinary assessments evaluate:
This enables investors to make evidence-based investment decisions while reducing technical, operational, manufacturing, and execution risk.
Where appropriate, Esco Aster can continue supporting portfolio companies through fractional executive leadership to accelerate execution following investment.
We support governments, innovation agencies, and research funding organisations by providing independent technical assessments that ensure public funding is allocated to projects with strong scientific merit, commercial potential, and societal impact. Our experts regularly contribute to grant evaluations, accelerator programmes, incubators, and innovation panels.
We help mission-driven organisations evaluate research programmes and mission impact investments to ensure alignment with their strategic objectives, patient impact, and measurable societal outcomes.
We support corporate innovation programmes, corporate venture capital, strategic partnerships, licensing evaluations, and venture creation initiatives by providing objective technical assessments aligned with corporate strategy, long-term innovation goals, and acquisition opportunities.
Esco Aster provides independent scientific, technical, operational, manufacturing, and commercial due diligence.
We do not provide regulated financial advisory, investment advisory, securities advisory, or corporate finance services. Esco Aster is not licensed by the Monetary Authority of Singapore (MAS) as a Financial Adviser and does not hold a Capital Markets Services (CMS) licence. Our services should therefore be considered technical and strategic advisory rather than regulated financial advice.
Investment decisions in biotechnology are only as strong as the quality of the technical diligence underpinning them.
Esco Aster combines deep scientific expertise with commercial, regulatory, manufacturing, and operational experience to provide independent, multidisciplinary due diligence that enables stakeholders to identify opportunities, minimise risk, allocate capital efficiently, and maximise long-term value creation.
By bridging research, clinical development, manufacturing, commercialisation, and investment, we help transform promising science into investable, scalable, and commercially successful biotechnology companies.